Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00605280




Registration number
NCT00605280
Ethics application status
Date submitted
18/01/2008
Date registered
31/01/2008
Date last updated
16/11/2018

Titles & IDs
Public title
A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.
Scientific title
A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, In Parallel Groups, To Compare The Safety And Efficacy Of Intravitreous Injections Of 0.3 Mg Pegaptanib Sodium (Macugen®), Given As Often As Every 6 Weeks For 2 Years, To Sham Injections In Subjects With Diabetic Macular Edema (DME) Involving The Center Of The Macula With An Open-Label Macugen Year 3 Extension.
Secondary ID [1] 0 0
EOP1013H
Secondary ID [2] 0 0
A5751013
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Macular Edema Associated With Diabetes Mellitus 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Standard of Care
Treatment: Drugs - Macugen

Sham comparator: Sham Control -

Experimental: Macugen -


Treatment: Drugs: Standard of Care
Clinicians decision to use optional laser therapy.

Treatment: Drugs: Macugen
Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Greater Than or Equal to =10 Letter (or 2 Line) Improvement in Vision at 1 Year
Timepoint [1] 0 0
Baseline, Year 1
Secondary outcome [1] 0 0
Number of Participants With a = 10 Letter (or 2 Line) Improvement in Vision at 2 Years
Timepoint [1] 0 0
Baseline, Year 2
Secondary outcome [2] 0 0
Number of Participants With a = 15 Letter Improvement in Vision at 1 Year
Timepoint [2] 0 0
Baseline, Year 1
Secondary outcome [3] 0 0
Number of Participants With a = 15 Letter Improvement in Vision at 2 Years
Timepoint [3] 0 0
Baseline, Year 2
Secondary outcome [4] 0 0
Number of Eyes With a 2 or More Step Increase in Degree of Retinopathy at 1 Year
Timepoint [4] 0 0
Baseline, Year 1
Secondary outcome [5] 0 0
Number of Eyes With a 2 or More Step Decrease in Degree of Retinopathy at 1 Year
Timepoint [5] 0 0
Baseline, Year 1
Secondary outcome [6] 0 0
Number of Eyes With a 2 or More Step Increase in Degree of Retinopathy at 2 Years
Timepoint [6] 0 0
Baseline, Year 2
Secondary outcome [7] 0 0
Number of Eyes With a 2 or More Step Decrease in Degree of Retinopathy at 2 Years
Timepoint [7] 0 0
Baseline, Year 2
Secondary outcome [8] 0 0
Change From Baseline in Mean VA Score at 1 Year
Timepoint [8] 0 0
Baseline, Year 1
Secondary outcome [9] 0 0
Change From Baseline in Mean VA Score at 2 Years
Timepoint [9] 0 0
Baseline, Year 2
Secondary outcome [10] 0 0
Number of Participants Requiring Focal or Grid Laser Treatment During Year 1
Timepoint [10] 0 0
1 year
Secondary outcome [11] 0 0
Number of Participants Requiring Focal or Grid Laser Treatment During Year 2
Timepoint [11] 0 0
2 years

Eligibility
Key inclusion criteria
* macular edema associated with diabetes
* visual acuity between 20/50 and 20/200
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* recent laser therapy in the eye
* recent signs of uncontrolled diabetes
* blood pressure worse than 160/100
* severe cardiac disease

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2005
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/07/2011
Sample size
Target
Accrual to date
Final
317
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Pfizer Investigational Site - Westmead
Recruitment hospital [2] 0 0
Pfizer Investigational Site - East Melbourne
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment postcode(s) [2] 0 0
- East Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Hawaii
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Wisconsin
Country [18] 0 0
Austria
State/province [18] 0 0
Innsbruck
Country [19] 0 0
Austria
State/province [19] 0 0
Wien
Country [20] 0 0
Brazil
State/province [20] 0 0
GO
Country [21] 0 0
Brazil
State/province [21] 0 0
Porto Alegre
Country [22] 0 0
Brazil
State/province [22] 0 0
Sao Paolo
Country [23] 0 0
Brazil
State/province [23] 0 0
Sao Paulo
Country [24] 0 0
Canada
State/province [24] 0 0
British Columbia
Country [25] 0 0
Canada
State/province [25] 0 0
Quebec
Country [26] 0 0
Colombia
State/province [26] 0 0
Bogota
Country [27] 0 0
Czechia
State/province [27] 0 0
Brno
Country [28] 0 0
Czechia
State/province [28] 0 0
Hradec Kralove
Country [29] 0 0
Czechia
State/province [29] 0 0
Olomouc
Country [30] 0 0
Czechia
State/province [30] 0 0
Praha 4
Country [31] 0 0
Czechia
State/province [31] 0 0
Praha 6
Country [32] 0 0
Denmark
State/province [32] 0 0
Glostrup
Country [33] 0 0
France
State/province [33] 0 0
Cedex
Country [34] 0 0
France
State/province [34] 0 0
Clermont
Country [35] 0 0
France
State/province [35] 0 0
Lyon
Country [36] 0 0
France
State/province [36] 0 0
Marseille Cedex 5
Country [37] 0 0
France
State/province [37] 0 0
Marseille
Country [38] 0 0
France
State/province [38] 0 0
Marsielle
Country [39] 0 0
France
State/province [39] 0 0
Nancy Cedex
Country [40] 0 0
France
State/province [40] 0 0
Paris Cedex 12
Country [41] 0 0
Germany
State/province [41] 0 0
Bonn
Country [42] 0 0
Germany
State/province [42] 0 0
Duesseldorf
Country [43] 0 0
Germany
State/province [43] 0 0
Heidelberg
Country [44] 0 0
Germany
State/province [44] 0 0
Leipzig
Country [45] 0 0
Germany
State/province [45] 0 0
Muenster
Country [46] 0 0
Germany
State/province [46] 0 0
Tuebingen
Country [47] 0 0
Greece
State/province [47] 0 0
Athens
Country [48] 0 0
India
State/province [48] 0 0
Ahmedabad
Country [49] 0 0
India
State/province [49] 0 0
Bangalore
Country [50] 0 0
India
State/province [50] 0 0
Hyderabad
Country [51] 0 0
India
State/province [51] 0 0
New Delhi
Country [52] 0 0
Italy
State/province [52] 0 0
Firenze
Country [53] 0 0
Italy
State/province [53] 0 0
Milano
Country [54] 0 0
Italy
State/province [54] 0 0
Udine
Country [55] 0 0
Netherlands
State/province [55] 0 0
Nijmegen
Country [56] 0 0
Portugal
State/province [56] 0 0
Coimbra
Country [57] 0 0
South Africa
State/province [57] 0 0
Bloemfontein
Country [58] 0 0
Switzerland
State/province [58] 0 0
Bern
Country [59] 0 0
United Kingdom
State/province [59] 0 0
Newcastle Upon Tyne
Country [60] 0 0
United Kingdom
State/province [60] 0 0
Sheffield

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is to test whether Macugen injected into the eye improves vision in more patients than the currently existing standard of care laser therapy. The safety of Macugen compared to standard of care laser will also be evaluated.
Trial website
https://clinicaltrials.gov/study/NCT00605280
Trial related presentations / publications
Loftus JV, Sultan MB, Pleil AM; Macugen 1013 Study Group. Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham. Invest Ophthalmol Vis Sci. 2011 Sep 29;52(10):7498-505. doi: 10.1167/iovs.11-7613.
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00605280